CD5 and diffuse large B-cell lymphoma: The patients in this study received standard R-CHOP/R-CHOP-like (n = 22 for CD5- DLBCL; n = 21 for CD5+ DLBCL) or R-based intensive regimens (n = 1 for CD5- DLBCL; n = 3 for CD5+ DLBCL) with two patients in each group receiving central nervous system (CNS) prophylaxis through methotrexate (MTX).